Vantage Investment Advisors’s Ocular Therapeutix OCUL Stock Holding History

Vantage Investment Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$25K	Hold	3,605	–	–	0.01%	389
2018 Q2	$24K	Hold	3,605	–	–	0.01%	383
2018 Q1	$23K	Hold	3,605	–	–	0.01%	401
2017 Q4	$16K	Hold	3,605	–	–	﹤0.01%	486
2017 Q3	$22K	Hold	3,605	–	–	0.01%	422
2017 Q2	$33K	Hold	3,605	–	–	0.01%	335
2017 Q1	$33K	Hold	3,605	–	–	0.01%	318
2016 Q4	$30K	Hold	3,605	–	–	0.01%	336
2016 Q3	$25K	Hold	3,605	–	–	0.01%	355
2016 Q2	$18K	Buy	3,605 +3,505	+3,505%	+$34.7K	0.01%	436
2016 Q1	$1K	Hold	100	–	–	﹤0.01%	771
2015 Q4	$1K	Hold	100	–	–	﹤0.01%	743
2015 Q3	$1K	Buy	+100	New	+$2.01K	﹤0.01%	747

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Vantage Investment Advisors's OCUL Position: Q3 2018 in Review

Vantage Investment Advisors held its Ocular Therapeutix (OCUL) position steady in Q3 2018 at 3,605 shares worth $25K. The position accounts for 0.01% of the portfolio, ranked #389.

Vantage Investment Advisors first reported a position in OCUL in Q3 2015 and has held it in 13 quarters since. The position peaked at $33K in Q2 2017. 73 funds tracked by Wall St. Rank hold OCUL as of Q3 2018.

Vantage Investment Advisors held 3,605 shares of Ocular Therapeutix worth $25K as of Q3 2018.
Vantage Investment Advisors left its Ocular Therapeutix share count unchanged in Q3 2018.
Ocular Therapeutix made up 0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #389 holding.
Vantage Investment Advisors first reported a position in Ocular Therapeutix in Q3 2015 and has held it in 13 quarters since.
Vantage Investment Advisors's Ocular Therapeutix position peaked at $33K in Q2 2017.
73 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.